Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Originally developed for treatment of type 2 diabetes in 2004, and later approved for weight loss in 2014, GLP-1s have demonstrated clinically meaningful reductions in A1c as well as unprecedented weight loss, with patients losing up to 20% of t heir body weight. There has been rapid adoption and a surge in demand for incretin-based therapies
Persistent vomiting or diarrhoea can lead to dehydration, which may increase the risk of acute kidney injury, particularly in individuals with pre-existing renal impairment
Managing cardiovascular risk We have a little while to wait for SURPASS-CVOT, the cardiovascular outcomes trial for tirzepatide, an active-comparator study versus dulaglutide 1.5 mg weekly, which is ongoing
US$ 23.22
US$ 23.33
US$ 21.69
US$ 29.82
